INTEGRARE represents the academic research of Genethon, a leading non-profit R&D organization developing gene therapy for genetic diseases. Genethon is located in the south of Paris, France.
INTEGRARE stands for "Integrated genetic approaches in therapeutic discovery for rare diseases". By studying biological systems, pathophysiological mechanisms and technological aspects, researchers develop treatments for genetic disorders affecting skeletal muscle, metabolism, immune or blood systems. Integrare has a strong expertise in the use of recombinant viral gene transfer vectors (rAAV and lentiviral vectors) or CRISPR genome editing tools. Promising preclinical projects are developed into early phase clinical trials in partnership with Genethon's technological and clinical departments and with international networks of external collaborators.
INTEGRARE, also identified as UMR_S951, is a mixed research unit affiliated with Inserm the premier French public research institute on human health, with the local University of Evry/Université Paris Saclay and with École Pratique des Hautes Études. Situated within the Génopole biotechnology cluster of Evry, INTEGRARE has access to platforms including a new Inserm technological platform in genomic therapy.
At the academic level, INTEGRARE laboratories provide excellent training in state-of-the art facilities, among international teams and networks. INTEGRARE laboratories welcome highly-motivated students and collaborators.
If you are interested in joining us, please consult our "Opportunities" section.
Anne GALY, PhD
Director of INTEGRARE UMR_S951